Folia medica Cracoviensia · 2025
The influence of chronic hepatitis B virus infection on fatty acid composition in erythrocyte membranes and plasma, and its effect on lipoxin A4 and resolvin D1 levels.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gdula-Argasińska Joanna, Czepiel Jacek, Pietrzycka Agata, Jurczyszyn Artur, Wołkow Paweł, Borys Agnieszka, Stażyk Katarzyna, Bociąga-Jasik Monika
Аннотация
AIM: This study aimed to assess the impact of chronic hepatitis B on fatty acids (FA) composition in erythrocyte membranes (RBC) and plasma, and its effect on lipoxin A4 and resolvin D1 levels.
MATERIALS AND METHODS: Sixty participants were enrolled: 30 hepatitis B patients (15 with cirrhosis, 15 without) and 30 healthy controls. Fatty acids content in plasma and RBC membranes was analyzed by gas chromatography. Serum lipoxin A4 (LXA4) and resolvin D1 (RvD1) were measured via enzyme immunoassay. Principal component analysis (PCA) assessed correlations between fatty acid composition, LXA4 and RvD1 levels.
RESULTS: Hepatitis B patients with cirrhosis exhibited significantly lower plasma lipoxin A4 (1812 pg/mL) compared to controls (2230 pg/mL) and non-cirrhotic hepatitis B patients (2453 pg/mL). Plasma n-3 FA levels (15.4% vs. 8.7%) and the n-3/n-6 ratio (0.8 vs. 0.4) were significantly reduced in cirrhotic patients. PCA data revealed associations between LXA4 and saturated fatty acids, and between n-3 FA and RvD1 pathways, suggesting disrupted lipid-mediated inflammation resolution. Erythrocyte membranes showed elevated trans C18:1 in cirrhotic hepatitis B.
CONCLUSIONS: Chronic HBV infection, especially with cirrhosis, alters fatty acid profiles and reduces lipoxin A4 level, contributing to persistent hepatic inflammation and highlighting potential lipid-targeted therapies.
MATERIALS AND METHODS: Sixty participants were enrolled: 30 hepatitis B patients (15 with cirrhosis, 15 without) and 30 healthy controls. Fatty acids content in plasma and RBC membranes was analyzed by gas chromatography. Serum lipoxin A4 (LXA4) and resolvin D1 (RvD1) were measured via enzyme immunoassay. Principal component analysis (PCA) assessed correlations between fatty acid composition, LXA4 and RvD1 levels.
RESULTS: Hepatitis B patients with cirrhosis exhibited significantly lower plasma lipoxin A4 (1812 pg/mL) compared to controls (2230 pg/mL) and non-cirrhotic hepatitis B patients (2453 pg/mL). Plasma n-3 FA levels (15.4% vs. 8.7%) and the n-3/n-6 ratio (0.8 vs. 0.4) were significantly reduced in cirrhotic patients. PCA data revealed associations between LXA4 and saturated fatty acids, and between n-3 FA and RvD1 pathways, suggesting disrupted lipid-mediated inflammation resolution. Erythrocyte membranes showed elevated trans C18:1 in cirrhotic hepatitis B.
CONCLUSIONS: Chronic HBV infection, especially with cirrhosis, alters fatty acid profiles and reduces lipoxin A4 level, contributing to persistent hepatic inflammation and highlighting potential lipid-targeted therapies.